Your search history is turned on.
Date: May 8, 2024 07:44:15 EST Jurisdictions: Alberta, British Columbia, Quebec
Neural Therapeutics Receives Conditional Approval to Listing on the CSE and Announces Concurrent Financing Toronto, Ontario--(Newsfile Corp. - May 8, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental ailments related to substance use disorders, is pleased to announce that it has received condi...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Quebec
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Omar Gonzalez, Chief Financial Officer of Neural Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Neural Therapeutics Inc. (the issuer) for the interim period...
NEURAL THERAPEUTICS INC. INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JANUARY 31, 2024 March 28, 2024 NEURAL THERAPEUTICS INC. Interim Management's Discussion & Analysis Quarterly Highlights...
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Ian Campbell, Chief Executive Officer of Neural Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Neural Therapeutics Inc. (the issuer) for the interim period ...
NHII Consolidated financial statements January 31, 2020 FINAL.pdf Neural Therapeutics Inc. Condensed Interim Financial Statements Three and Six Months Ended January 31, 2024 (Expressed in Canadian Dollars, unless otherwise noted) Notice To ...
Date: December 22, 2023 Jurisdictions: Alberta, British Columbia, Quebec
Document2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Omar Gonzalez, Chief Financial Officer of Neural Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Neural Therapeutics Inc. (the issuer) for the in...
Document2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Ian Campbell, Chief Executive Officer of Neural Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Neural Therapeutics Inc. (the issuer) for the int...
NEURAL THERAPEUTICS INC. INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED OCTOBER 31, 2023 December 21, 2023 NEURAL THERAPEUTICS INC. Interim Management's Discussion & Analysis Quarterly Highl...
NHII Consolidated financial statements January 31, 2020 FINAL.pdf Neural Therapeutics Inc. Condensed Interim Financial Statements Three Months Ended October 31, 2023 (Expressed in Canadian Dollars, unless otherwise noted) Notice To Reader ...
Date: November 24, 2023 Jurisdictions: Alberta, British Columbia, Quebec
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Omar Gonzalez, Chief Financial Officer of Neural Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by refe...